Literature DB >> 24717909

Dopamine D₃ receptor alterations in cocaine-dependent humans imaged with [¹¹C](+)PHNO.

David Matuskey1, Jean-Dominique Gallezot2, Brian Pittman3, Wendol Williams4, Jane Wanyiri3, Edward Gaiser3, Dianne E Lee2, Jonas Hannestad3, Keunpoong Lim2, Minq-Qiang Zheng2, Shu-fei Lin2, David Labaree2, Marc N Potenza3, Richard E Carson2, Robert T Malison3, Yu-Shin Ding5.   

Abstract

BACKGROUND: Evidence from animal models and postmortem human studies points to the importance of the dopamine D₃ receptor (D₃R) in cocaine dependence (CD). The objective of this pilot study was to use the D₃R-preferring radioligand [(11)C](+)PHNO to compare receptor availability in groups with and without CD.
METHODS: Ten medically healthy, non-treatment seeking CD subjects (mean age 41 ± 8) in early abstinence were compared to 10 healthy control (HC) subjects (mean age 41 ± 6) with no history of cocaine or illicit substance abuse. Binding potential (BPND), a measure of available receptors, was determined with parametric images, computed using the simplified reference tissue model (SRTM2) with the cerebellum as the reference region.
RESULTS: BPND in CD subjects was higher in D₃R-rich areas including the substantia nigra ((SN) 29%; P=0.03), hypothalamus (28%; P=0.02) and amygdala (35%; P=0.03). No between-group differences were observed in the striatum or pallidum. BPND values in the SN (r=+0.83; P=0.008) and pallidum (r=+0.67; P=0.03) correlated with years of cocaine use.
CONCLUSIONS: Between-group differences suggest an important role for dopaminergic transmission in the SN, hypothalamus and amygdala in CD. Such findings also highlight the potential relevance of D₃R as a medication development target in CD.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cocaine; D(3); Dopamine; Human; PET; [(11)C](+)PHNO

Mesh:

Substances:

Year:  2014        PMID: 24717909      PMCID: PMC4071607          DOI: 10.1016/j.drugalcdep.2014.03.013

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  50 in total

1.  Dopamine D3-like receptors modulate anxiety-like behavior and regulate GABAergic transmission in the rat lateral/basolateral amygdala.

Authors:  Marvin R Diaz; Ann M Chappell; Daniel T Christian; Nancy J Anderson; Brian A McCool
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

2.  Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior.

Authors:  Janet L Neisewander; Rita A Fuchs; Ly T L Tran-Nguyen; Suzanne M Weber; Greg P Coffey; Jeffrey N Joyce
Journal:  Neuropsychopharmacology       Date:  2004-08       Impact factor: 7.853

3.  Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.

Authors:  Graham Searle; John D Beaver; Robert A Comley; Massimo Bani; Andri Tziortzi; Mark Slifstein; Manolo Mugnaini; Cristiana Griffante; Alan A Wilson; Emilio Merlo-Pich; Sylvain Houle; Roger Gunn; Eugenii A Rabiner; Marc Laruelle
Journal:  Biol Psychiatry       Date:  2010-08-15       Impact factor: 13.382

4.  Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study.

Authors:  A Schotte; P F Janssen; P Bonaventure; J E Leysen
Journal:  Histochem J       Date:  1996-11

Review 5.  Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.

Authors:  Christian A Heidbreder; Amy H Newman
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

6.  Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment.

Authors:  Diana Martinez; Kenneth M Carpenter; Fei Liu; Mark Slifstein; Allegra Broft; Alessandra Calvo Friedman; Dileep Kumar; Ronald Van Heertum; Herbert D Kleber; Edward Nunes
Journal:  Am J Psychiatry       Date:  2011-03-15       Impact factor: 18.112

7.  Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy.

Authors:  Andri C Tziortzi; Graham E Searle; Sofia Tzimopoulou; Cristian Salinas; John D Beaver; Mark Jenkinson; Marc Laruelle; Eugenii A Rabiner; Roger N Gunn
Journal:  Neuroimage       Date:  2010-06-30       Impact factor: 6.556

8.  Mesocorticolimbic circuits are impaired in chronic cocaine users as demonstrated by resting-state functional connectivity.

Authors:  Hong Gu; Betty Jo Salmeron; Thomas J Ross; Xiujuan Geng; Wang Zhan; Elliot A Stein; Yihong Yang
Journal:  Neuroimage       Date:  2010-07-11       Impact factor: 6.556

9.  Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities.

Authors:  J K Staley; D C Mash
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

10.  Modulation of cocaine self-administration in the rat through D-3 dopamine receptors.

Authors:  S B Caine; G F Koob
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

View more
  35 in total

1.  Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Authors:  David Matuskey; Patrick Worhunksy; Elizabeth Correa; Brian Pittman; Jean-Dominique Gallezot; Nabeel Nabulsi; Jim Ropchan; Venkatesh Sreeram; Rohit Gudepu; Edward Gaiser; Kelly Cosgrove; Yu-Shin Ding; Marc N Potenza; Yiyun Huang; Robert T Malison; Richard E Carson
Journal:  Neuroimage       Date:  2016-02-11       Impact factor: 6.556

2.  Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Authors:  Isabelle Boileau; Doris Payer; Pablo M Rusjan; Sylvain Houle; Junchao Tong; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

Review 3.  What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?

Authors:  Mayako Michino; Thijs Beuming; Prashant Donthamsetti; Amy Hauck Newman; Jonathan A Javitch; Lei Shi
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

4.  Correlates of polysomnographic sleep changes in cocaine dependence: self-administration and clinical outcomes.

Authors:  Gustavo A Angarita; Sofija V Canavan; Erica Forselius; Andrew Bessette; Peter T Morgan
Journal:  Drug Alcohol Depend       Date:  2014-07-30       Impact factor: 4.492

5.  Genetic deletion of the dopamine D3 receptor increases vulnerability to heroin in mice.

Authors:  Jia Zhan; Chloe J Jordan; Guo-Hua Bi; Xiang-Hu He; Eliot L Gardner; Yan-Lin Wang; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2018-08-20       Impact factor: 5.250

Review 6.  CNS metabolism in high-risk drug abuse : Insights gained from 1H-, 31P-MRS and PET.

Authors:  S Bodea
Journal:  Radiologe       Date:  2018-11       Impact factor: 0.635

Review 7.  A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate.

Authors:  Thulasi Thiruchselvam; Saima Malik; Bernard Le Foll
Journal:  Am J Drug Alcohol Abuse       Date:  2016-11-30       Impact factor: 3.829

Review 8.  [CNS metabolism in high-risk drug abuse, German version : Insights gained from 1H- and 31P MRS and PET].

Authors:  S V Bodea
Journal:  Radiologe       Date:  2017-06       Impact factor: 0.635

9.  Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making.

Authors:  Stephanie M Groman; Nathaniel J Smith; J Ryan Petrullli; Bart Massi; Lihui Chen; Jim Ropchan; Yiyun Huang; Daeyeol Lee; Evan D Morris; Jane R Taylor
Journal:  J Neurosci       Date:  2016-06-22       Impact factor: 6.167

10.  Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO.

Authors:  Edward C Gaiser; Jean-Dominique Gallezot; Patrick D Worhunsky; Ania M Jastreboff; Brian Pittman; Lauren Kantrovitz; Gustavo A Angarita; Kelly P Cosgrove; Marc N Potenza; Robert T Malison; Richard E Carson; David Matuskey
Journal:  Neuropsychopharmacology       Date:  2016-07-04       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.